glp 1 agonist cardiovascular outcomes outcome studies with GLP-1 receptor GLP-1 receptor agonist versus DPP-4

However, no direct link has been found between GLP-1R agonists and higher pulmonary aspiration risk

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

See if you qualify

The best results happen when the medicine is used along with healthy eating and exercise, and people may gain weight back if they stop taking the medicine

Mark Cuban Cost Plus Drug Company.